EMAIL THIS PAGE TO A FRIEND

Biochemical and biophysical research communications

Glycosylation inhibitors block the expression of LAV/HTLV-III (HIV) glycoproteins.


PMID 3099781

Abstract

The glycosylation inhibitors 2-deoxy-D-glucose (2-dGlc) and, to a lesser extent, beta-hydroxynorvaline blocked the formation of syncytia in HIV (LAV/HTLV-III)-infected cells. Using monospecific polyclonal antibodies against recombinant envelope proteins gp110 and gp41 or monoclonal antibodies against env gp110, we could demonstrate a marked reduction in the immunoreactivity of these antigens in HIV-infected cells exposed to the glycosylation inhibitors. There was concomitant accumulation of core proteins p15 and p24, as shown by a solid phase radio-immunoassay, and a decreased oligosaccharide synthesis of env proteins, as monitored by the incorporation of [6-3H]GlcNAc. The reverse transcriptase was not affected by the compounds. Glycosylation inhibitors may be considered for the chemotherapy of AIDS or AIDS-related complex, or chemoprophylaxis of HIV-positive individuals.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

H4002
DL-3-Hydroxynorvaline, ≥98% (TLC)
C5H11NO3